Temozolomide-capecitabine chemotherapy for neuroendocrine neoplasms: the dilemma of treatment duration
Authors
Lamarca, AngelaBarriuso, Jorge
McNamara, Mairéad G
Hubner, Richard A
Manoharan, Prakash
Mansoor, Was
Valle, Juan W
Affiliation
Department of Medical Oncology, The Christie NHS Foundation Trust, ManchesterIssue Date
2020
Metadata
Show full item recordCitation
Lamarca A, Barriuso J, McNamara MG, Hubner RA, Manoharan P, Mansoor W, et al. Temozolomide-Capecitabine Chemotherapy for Neuroendocrine Neoplasms: The Dilemma of Treatment Duration. Neuroendocrinology. 2020;110(1-2):155-7.Journal
NeuroendocrinologyDOI
10.1159/000503392PubMed ID
31527383Additional Links
https://dx.doi.org/10.1159/000503392Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1159/000503392